Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio.

Literature DB >> 8354015

Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio.

P E Lønning¹.

Abstract

Mesh：

Substances：

Year: 1993 PMID： 8354015 DOI： 10.2165/00003088-199325010-00001

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

7 in total

1. Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.

Authors: J Bonneterre; H Coppens; L Mauriac; M Metz; J Rouesse; J P Armand; P Fargeot; M Mathieu; M Tubiana; P Cappelaere
Journal: Eur J Cancer Clin Oncol Date: 1985-10

2. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.

Authors: C J Gallagher; F Cairnduff; I E Smith
Journal: Eur J Cancer Clin Oncol Date: 1987-12

3. Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors: P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal: Clin Pharmacokinet Date: 1985 Jul-Aug Impact factor: 6.447

4. Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.

Authors: E Strocchi; C M Camaggi; A Martoni; R Cellerino; S Miseria; P Malacarne; M Indelli; M Balli; G Bonciarelli; G Ambroso
Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333

Review 5. Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.

Authors: D R Newell
Journal: Br J Cancer Date: 1990-02 Impact factor: 7.640

6. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.

Authors: P F Bruning; J M Bonfrer; A A Hart; E van der Linden; M de Jong-Bakker; A J Moolenaar; W J Nooijen
Journal: Eur J Cancer Clin Oncol Date: 1989-02

7. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.

Authors: H van Veelen; P H Willemse; D T Sleijfer; W J Sluiter; H Doorenbos
Journal: Cancer Treat Rep Date: 1985-09

7 in total

4 in total

Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio.

1. Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.

2. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.

3. Single-dose and steady-state pharmacokinetics of aminoglutethimide.

4. Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.

Review 5. Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.

6. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.

7. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.

Review 1. Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Review 2. Concentration-controlled trials. What does the future hold?

Review 3. Paediatric labelling requirements. Implications for pharmacokinetic studies.

4. Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.